Vital signs: Pharmacy-based naloxone dispensing — United States, 2012–2018

Morbidity and Mortality Weekly Report

Volumn 68, Issue 31, 2019, Pages 679-686

  Guy, Gery P ^a   Haegerich, Tamara M ^a   Evans, Mary E ^a   Losby, Jan L ^a   Young, Randall ^b   Jones, Christopher M ^a  

^a NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL   (United States)

^b AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONE;

ADOLESCENT; ADULT; AGED; CHILD; DRUG OVERDOSE; EPIDEMIC; EPIDEMIOLOGY; FEMALE; HUMAN; INFANT; MALE; MIDDLE AGED; MORTALITY; NEWBORN; OPIATE ADDICTION; PHARMACY (SHOP); PRESCHOOL CHILD; PRESCRIPTION; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG OVERDOSE; EPIDEMICS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NALOXONE; OPIOID-RELATED DISORDERS; PHARMACIES; PRESCRIPTIONS; UNITED STATES; YOUNG ADULT;

EID: 85071172826     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/MMWR.MM6831E1     Document Type: Article

References (23)

1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb Mortal Wkly Rep 2018;67:1419–27. https://doi.org/10.15585/mmwr. mm675152e1
2. CDC. 2018 Annual surveillance report of drug-related risks and outcomes—United States. Surveillance special report. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf
3. Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. Drug overdose deaths involving cocaine and psychostimulants with abuse potential—United States, 2003–2017. MMWR Morb Mortal Wkly Rep 2019;68:388–95. https://doi.org/10.15585/mmwr.mm6817a3
4. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1). https://doi.org/10.15585/mmwr.rr6501e1
5. US Department of Health and Human Services. Strategy to combat opioid abuse, misuse, and overdose. Washington, DC: US Department of Health and Human Services; 2018. https://www.hhs.gov/opioids/sites/default/files/2018-09/opioid-fivepoint-strategy-20180917-508compliant.pdf
6. Prescription Drug Abuse Policy System. Naloxone overdose prevention laws. Philadelphia, PA: Prescription Drug Abuse Policy System; 2017. http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139
7. Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend 2018;189:37–41. https://doi.org/10.1016/j.drugalcdep.2018.04.020
8. Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR. Association of naloxone copresciption laws with naloxone prescription dispensing in the United States. JAMA Netw Open 2019;2:e196215. https://doi.org/10.1001/jamanetworkopen.2019.6215
9. Guy GP Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697–704. https://doi.org/10.15585/mmwr. mm6626a4
10. CDC, National Center for Health Statistics. NCHS urban-rural classification scheme for counties. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2019. https://www.cdc.gov/nchs/data_access/urban_rural.htm
11. Bohnert ASB, Guy GP Jr, Losby JL. Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 opioid guideline. Ann Intern Med 2018;169:367–75. https://doi.org/10.7326/M18-1243
12. Abouk R, Pacula RL, Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med 2019;179:805. https://doi.org/10.1001/jamainternmed.2019.0272
13. Faul M, Dailey MW, Sugerman DE, Sasser SM, Levy B, Paulozzi LJ. Disparity in naloxone administration by emergency medical service providers and the burden of drug overdose in US rural communities. Am J Public Health 2015;105(Suppl 3):e26–32. https://doi.org/10.2105/AJPH.2014.302520
14. Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. MMWR Morb Mortal Wkly Rep 2015;64:1337–41. https://doi.org/10.15585/mmwr.mm6448a3
15. Binswanger IA, Koester S, Mueller SR, Gardner EM, Goddard K, Glanz JM. Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med 2015;30:1837–44. https://doi.org/10.1007/s11606-015-3394-3
16. Behar E, Rowe C, Santos GM, Santos N, Coffin PO. Academic detailing pilot for naloxone prescribing among primary care providers in San Francisco. Fam Med 2017;49:122–6.
17. Furlan AD, Zhao J, Voth J, et al. Evaluation of an innovative teleeducation intervention in chronic pain management for primary care clinicians practicing in underserved areas. J Telemed Telecare 2018;24:1357633X18782090.https://doi.org/10.1177/1357633X18782090
18. Marino R, Landau A, Lynch M, Callaway C, Suffoletto B. Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose? Addiction 2019. Epub April 23, 2002. https://doi.org/10.1111/add.14635
19. Gupta R, Shah ND, Ross JS. The rising price of naloxone—risks to efforts to stem overdose deaths. N Engl J Med 2016;375:2213–5. https://doi.org/10.1056/NEJMp1609578
20. Jones CM, Compton W, Vythilingam M, Giroir B. Naloxone co-prescribing to patients receiving 2 prescription opioids in the Medicare Part D 3 program, United States, 2016–2017. JAMA 2019;322:462–4.
21. Centers for Medicare and Medicaid Services. 2020 Medicare advantage and part D rate announcement and final call letter fact sheet. Baltimore, MD: US Department of Health and Human Services, Centers for Medicare and Medicaid Services; 2019. https://www.cms.gov/newsroom/fact-sheets/2020-medicare-advantage-and-part-d-rate-announcement- and-final-call-letter-fact-sheet
22. US Department of Health and Human Services. U.S. Surgeon General’s advisory on naloxone and opioid overdose. Washington, DC: US Department of Health and Human Services; 2018. https://www.hhs.gov/surgeongeneral/priorities/opioids-and-addiction/naloxone-advisory/ index.html
23. US Department of Health and Human Services. Naloxone: the opioid reversal drug that saves lives. Washington, DC: US Department of Health and Human Services; 2018. https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf